Regeneron builds preventive case for Eylea with new 2-year data

Eylea
The FDA granted Eylea an approval in diabetic retinopathy back in May. (Regeneron)

Despite facing a highly touted competitor in Novartis' Beovu, Regeneron hasn't broken a sweat as blockbuster eye med Eylea continues to gobble up market share. Already in the lead in multiple indications, new two-year data could help Regeneron make the case for its drug in the preventive setting as well. 

After two years, injectable Eylea sliced the risk of vision-threatening complications by 75% over placebo in patients with non-proliferative diabetic retinopathy, according to phase 3 data released Friday. 

Regeneron touted the data as a case for physicians to use Eylea preventively, as 58% of patients in the phase 3 Panorama trial's control arm developed diabetic macular edema or compromised vision at the two-year mark. 

Webinar

Bioavailability Enhancement – Industry Insights, Key Challenges & Advanced Development Solutions

Join this webcast on Tuesday, June 16 as experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.

The FDA approved Eylea in May to treat all stages of diabetic retinopathy, a condition that affects about 8 million people worldwide and is the leading cause of blindness in U.S. adults, the company said.

The administration based its nod on six- and 12-month data from the Panorama study showing Eylea significantly cut the risk of patients developing proliferative diabetic retinopathy when treated every eight and 16 weeks. 

RELATED: Can Regeneron weather Novartis' Eylea rival and Praluent new deal? No worries, says exec

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Moderna is entering an important time, its CEO says. And the company is doing so with a new finance chief from Big Biotech.